As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…
Search results for: Tofacitinib
An Evidence-Based Drug Update & Guidance for Rheumatologists
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
A Guiding Light for RA: Insights into Clinical Decision Making, Drug Safety & More
The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.
Just in Case: Understanding Rheumatoid Arthritis Through Patient Cases
Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
JAK Inhibitors: Are All Promises Fulfilled?
A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.
Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
Conservation of Drugs: The Impact of Acute Immunomodulator Prescribing for COVID-19 on Rheumatology Patients
In its COVID-19 treatment guidelines, the National Institutes of Health (NIH) lists several drugs commonly prescribed for patients with rheumatic conditions as potential therapies in those who are hospitalized for COVID-19 and require high-flow oxygen, noninvasive ventilation, intermittent ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), as of Aug. 25, 2021, and current as this is…
Medication Preferences & Current Practices for PsA
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
2 New Clinical Practice Guidelines for JIA Released
Two new ACR Clinical Practice Guidelines provide recommendations on the pharmacologic management of JIA, focusing on treatment of oligoarthritis, temporomandibular arthritis & systemic JIA, as well as nonpharmacologic therapies, medication monitoring, immunizations & imaging.
Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at Johns Hopkins School of Medicine, Baltimore, Atul Deodhar, MD, discussed ankylosing spondylitis and non-radiographic axial spondyloarthritis & clarified common misconceptions about these conditions.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »